Bristol-Myers Squibb's (BMY) 'Disappointing' Opdivo Data in NSCLC has No Impact on Ratings - Moody's

August 5, 2016 3:48 PM EDT

Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.

Moody's Investors Service commented that Bristol-Myers Squibb's (NYSE: BMY) disappointing clinical trial result for Opdivo in first-line lung cancer is a setback because this indication represented a sizeable growth opportunity. There is no impact on Bristol's A2/Prime-1 ratings or stable rating outlook.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Credit Ratings

Related Entities

Moody's Investors Service

Add Your Comment